GlassScriptPhysician profile
James Russ Moore
NPI 1164904397
$1,862.37
in general payments reported to CMS, 2019-2025
14 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $336 · 2023: $413 · 2024: $414 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $547.35 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $460.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.37 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $173.22 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $108.27 | 2023 | |
| Pfizer INC. | $85.58 | 2023-2025 | |
| Amgen INC. | $74.63 | 2023-2024 | Repatha, Otezla |
| Exeltis, USA INC. | $46.47 | 2025 | Slynd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.37 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $23.14 | 2025 | Qelbree |
| Phathom Pharmaceuticals, INC. | $19.60 | 2025 | Voquezna |
| Exact Sciences Corporation | $18.23 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2023 | Jardiance |
| Mylan Pharmaceuticals INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.